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Background:Marijuana is seeing increased therapeutic use, and is the world's third most-popular recreational
drug following alcohol and tobacco. This widening use poses increased exposure to potentially toxic combustion
by-products from marijuana smoke and the potential for public health concerns.
Objectives: To compare urinary metabolites of polycyclic aromatic hydrocarbons (PAHs) and volatile organic
compounds (VOCs) among self-reported recent marijuana users and nonusers, while accounting for tobacco
smoke exposure.
Methods:Measurements of PAH and VOC metabolites in urine samples were combined with questionnaire data
collected from participants in the National Health and Nutrition Examination Surveys (NHANES) from 2005 to
2012 in order to categorize participants (≥18 years) into exclusive recent marijuana users and nonusers.
Adjusted geometric means (GMs) of urinary concentrations were computed for these groups using multiple
regression analyses to adjust for potential confounders.
Results: Adjusted GMs of many individual monohydroxy PAHs (OH-PAHs) were significantly higher in recent
marijuana users than in nonusers (p b 0.05). Urinary thiocyanate (p b 0.001) and urinary concentrations of
many VOC metabolites, including metabolites of acrylonitrile (p b 0.001) and acrylamide (p b 0.001),
were significantly higher in recent marijuana users than in nonusers.
Conclusions: We found elevated levels of biomarkers for potentially harmful chemicals among
self-identified, recent marijuana users compared with nonusers. These findings suggest that further studies
are needed to evaluate the potential health risks to humans from the exposure to these agents when
smoking marijuana.
Published by Elsevier Ltd.
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1. Introduction
Marijuana, prepared from Cannabis sativa, has been increasingly
used as a therapeutic agent, and ranks as the world's third most-
popular recreational drug following alcohol and tobacco (Murray
et al., 2007; UNODC, 2014). The United Nations Office on Drugs and
Crime (UNODC) estimated that worldwide 177 million people aged
15–64 years used cannabis at least once in 2012 (UNODC, 2014).
Marijuana use in the USA was allowed for medical purpose under
Federal law in 1937 when the Marijuana Tax Act was passed.
In 1942, marijuana was removed from the US pharmacopeia, and in
1970, it was classified as a drug with ‘no accepted medical use’
(Murray et al., 2007). Since California became the first state to
legalize medical marijuana use in 1996, 23 states and the District of
Columbia in US have legalized medical marijuana use. In contrast
with past-month tobacco use among persons ≥12 years old in US,
which decreased from 30.4% in 2002 to 25.5% in 2013, the proportion
using marijuana in the past month increased from 6.2% in 2002 to
7.5% in 2013 (SAMHSA, 2014).
Most people use marijuana for medical and recreational activities
because it contains psychoactive constituents such as the primary
cannabinoid — Δ9-tetrahydrocannabinol (THC) (Murray et al., 2007).
Medicinally, marijuana is used to relieve symptoms, such as nausea
and vomiting caused by cancer chemotherapy, appetite loss in
patients with AIDS, muscle spasticity and chronic pain in patients
with neurological disorders, and glaucoma (Hall and Degenhardt,
2003). Recreationally, the use of marijuana can provide temporary
experiences, including euphoria, relaxation, heightened mood (Hall
and Degenhardt, 2009). Use of marijuana can also cause many
adverse health consequences, including anxiety and panic in naive
users (Hall and Degenhardt, 2009), impaired respiratory function
(Taylor et al., 2002), chronic bronchitis (Tetrault et al., 2007), elevat-
ed risks of increased heart rate (Jones, 2002) and myocardial infarc-
tion (Mittleman et al., 2001), and possibly lung cancer (Aldington
et al., 2008; Berthiller et al., 2008). Long-term marijuana use is also
associated with impaired cognitive abilities (Solowij et al., 2002),
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changes in brain function (Block et al., 2000), and use during
pregnancy has been associated with reduced birth weight in the
offspring, but not all studies (English et al., 1997; Fergusson et al.,
2002; Gray et al., 2010; Brown and Graves, 2013; Huizink, 2014;
Mark et al., 2015).
Similar to tobacco users, smoking is the main route desired by
many marijuana users as this is the most efficient way to achieve the
desired psychoactive effects within a short time (Huestis, 2002; Clark
et al., 2004; Ware et al., 2005; Hall and Degenhardt, 2009; Schauer
et al., 2015). Unlike cigarette smoke (i.e., main stream, side stream,
secondhand and even third-hand smoke) which has been extensively
investigated, information on chemical constituents produced through
smoking marijuana is limited (Fehr and Kalant, 1972; Lee et al., 1976;
Rickert et al., 1982; Chait and Pierri, 1989; Moir et al., 2008; Maertens
et al., 2009). Collectively, these studies have indicated that marijuana
smoke contains similar toxic chemical constituents as tobacco smoke,
including polycyclic aromatic hydrocarbons (PAHs) and volatile organic
compounds (VOCs). Nevertheless, existing literature data is insufficient
to evaluate actual body burdens of these harmful chemicals in
marijuana users.
In this study, we use self-reported questionnaire data along with
serum cotinine (sCOT) concentrations measured in adult participants
(≥18 years old) of the National Health and Nutrition Examination
Surveys (NHANES) during the period 2005 to 2012 to classify the
participants as exclusive marijuana users and nonusers of marijuana
or tobacco. We subsequently evaluated and compared the urinary
concentrations of PAH and VOC metabolites among them.
2. Materials and methods
2.1. Study design and participants
The National Center for Health Statistics (NCHS) of the Centers
for Disease Control and Prevention (CDC) conducts NHANES,
a cross-sectional health examination survey conducted in two-year
cycles; its sample is representative of the US civilian non-
institutionalized population. Survey participants are randomly
selected using a complex, stratified, multistage probability design.
A sample weight is assigned to each participant to account for the
complex survey design (including oversampling), survey non-
response, and post-stratification. Details on sample design and
weight calculation were described online by NCHS (US-CDC,
2013). The NCHS Research Ethics Review Board (ERB) protected
the rights and welfare of NHANES participants. In accordance
with Federal regulations, the NCHS ERB reviewed and approved
NHANES protocols and any changes made to them. Signed informed
consent was obtained from each participant or their parent/guardian
prior to collecting any data.
Participants included in this study were ≥18 years old. Monohydroxy
PAH metabolites (OH-PAHs) were measured in a subsample of
participants from four survey cycles: 2005–2006, 2007–2008,
2009–2010 and 2011–2012. Totally 9064 participants had all valid
measurements of OH-PAHs, urinary creatinine (UCre) and sCOT.
VOC metabolites were measured in a subsample of participants
from two survey cycles: 2005–2006 and 2011–2012. Totally, 5407
participants had all valid measurements of VOC metabolites, UCre
and sCOT. Urinary thiocyanate (SCN) was measured in participants
from four survey cycles: 2005–2006, 2007–2008, 2009–2010 and
2011–2012. Totally, 19,065 participants had all valid measurements
of SCN, UCre and sCOT. Urinary total 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanol (tNNAL) was measured in participants from
three survey cycles: 2007–2008, 2009–2010 and 2011–2012. Totally,
20,679 participants had all valid measurements of tNNAL, UCre
and sCOT.
Study participants were classified as non-tobacco users if their sCOT
levels were ≤10 ng/mL (Pirkle et al., 1996, 2006), and they reported not
using any tobacco or nicotine products (i.e., cigarette, cigar, pipe,
snuff, chewing tobacco, nicotine patch) within the five days prior
to their NHANES physical examination (Wei et al., under review,
2015b, 2015c). Among non-tobacco users, those who reported use
of marijuana within the five days prior to examination were classified
as recent marijuana users based on their responses to the question
“last time used marijuana or hashish”, and those who reported never
using marijuana were classified as nonusers if they responded “no” to
the question “ever used marijuana or hashish”. Those participants
who used marijuana at least once prior to examination but not within
the last five days were not included in either of those two groups.
Exclusive cigarette smokers were identified if their sCOT was
N10 ng/mL, and they self-reported cigarette smoking within the five
days prior to examination, but neither usedmarijuana nor any other to-
bacco products. Owing to the lack of the information regarding to how
marijuana products were consumed by the participants, we were
unable to conduct a ‘fine’ classification among marijuana users into
groups such as “marijuana smokers or users of edibles”. Fig. 1 shows
the classification tree for nonusers of marijuana or tobacco, recent
marijuana users and cigarette users, and their sample size characteristics
are given in Table 1.
2.2. Laboratory measurements
We measured urinary VOC metabolites using ultra-high perfor-
mance liquid chromatography (UPLC) coupled with electrospray
ionization (ESI) tandem mass spectrometry (UPLC-ESI/MSMS) with
limits of detection (LOD) ranging from 0.5 to 20 nanograms per mil-
liliter (ng/mL) (Alwis et al., 2012). We measured urinary SCN using
ion chromatography coupled with ESI-MS/MS with a LOD of
20 ng/mL (Blount and Valentin-Blasini, 2006; Valentín-Blasini
et al., 2007). We measured urinary OH-PAHs using isotope-dilution
gas chromatography (GC) coupled with MS or MS/MS with LODs in
the range of 1.0–19 picograms per milliliter (pg/mL) (Li et al., 2006,
2014). We measured sCOT using HPLC coupled with atmospheric
ionization (API)–MS/MS with a LOD of 0.015 ng/mL for all NHANES
participants (Bernert et al., 2000). We measured urinary tNNAL,
a major metabolite of 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK), using HPLC-ESI-MS/MS method with a LOD of
0.6 pg/mL (Xia et al., 2005). Urinary creatinine concentration was
measured using a colorimetric method based on Jaffé rate reaction.
Biological samples were collected, shipped and stored according to
strict quality assurance and quality control (QA/QC) rules that involved
both internal and external surveillance. For example, all collection
materials, vacuum sample vials, and storage containers used were
prescreened for background contamination levels (US-CDC, 2014a,
2014b). Laboratory blanks and QC samples were also simultaneously
processed and analyzed to assure the quality of the analytical results
to meet the accuracy and precision specification of the QC/QA program
of Division of Laboratory Sciences at the US CDC (Caudill et al., 2008).
2.3. Statistical analysis
Statistical analyses were conducted using SAS (version 9.3; SAS
Institute Inc., Cary, NC, USA) and SUDAAN (version 11.0.0; RTI
International, Research Triangle Park, NC, USA). Because we com-
bined multiple survey cycles, we first merged the data regarding
biomarker concentrations and those tobacco/marijuana associated
questionnaire data, and then calculated new sample weights for
each participant according to the recommendations of the NCHS
(US-CDC, 2014a, 2014b). Briefly, new sample weights equal to 1/n
of the sample weights provided in the NHANES, where n refers to
the total number of release cycles in which the biomarker concentra-
tions were available. In all of our analyses, statistics were adjusted
for the new sampling weights and the nonrandom sampling design.
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Both VOC and PAH metabolites were measured in participants from
a one-third sample of all participants while serum cotinine was
measured in all participants. Owing to the generally low response
rates to marijuana related questions, we were able to identify 47 and
73 recent marijuana users (use of marijuana within the last 5 days
prior to their NHANES physical examination) who had valid
measurements of sCOT, urinary creatinine (UCre), VOC and PAH
metabolites, respectively. This limited number of samples did not
allow us to systematically examine the associations between urinary
measurements and demographic (i.e. race and gender) or socioeconomic
(i.e. income and education) variables, but rather to evaluate whether the
overall differences between marijuana user and nonuser categories were
significant on the basis of expected large differences in biomarker levels
between these two groups. Nevertheless, in order to compare biomarker
levels among marijuana users and nonusers, sample weighted linear
regression models were used to estimate least-squares geometric
means (lsGMs) and 95% confidence intervals (95% CI) from log10
transformed urinary biomarker concentrations, with log10-sCOT
and log10-UCre as covariates. Log10-sCOT was included to account
for potential confounding from exposure to secondhand tobacco
smoke, and log10-UCre was included to account for variation arising
from urine dilutions among spot samples (Barr et al., 2005). The term
“adjusted” GMs was used to refer to lsGMs throughout the manu-
script. In addition, concentrations below the LOD were substituted
with the LOD divided by the square root of two. Statistical analysis
was confined to measurements with a frequency of detection greater
than 60% to avoid undue influence on the estimates caused by
imputed values. In all cases, using Satterwaite-adjusted F statistics,
difference in least-squares means among different groups with a
null hypothesis probability level of b0.05 was considered as
statistical significance.
3. Results
OH-PAHswere detected in nearly all urine samples nonusers, recent
marijuana users and cigarette smokers from NHANES 2005–2012
(Table 2). Most of the VOC metabolites were detected in ≥62% urine
samples. Benzene metabolites, trans, trans-muconic acid (MU) and
N-acetyl-S-(phenyl)-L-cysteine (PMA), were only detected in 51.2%
and 29.5% respectively in urine samples from recent marijuana
users. Cigarette smokers had higher detection rates for MU (69%)
and PMA (43%).
Fig. 2 shows GMs of tNNAL concentrations among different
marijuana use status groups. Without including log10-sCOT in the
regression analysis, we found recent marijuana users had a signifi-
cantly higher adjusted GM of tNNAL (2.13 pg/mL) than nonusers
(0.96 pg/mL). After adding log-sCOT in the regression analysis as a
covariate, no significant statistical differences in adjusted GMs
were observed between recent marijuana users and nonuser groups.
Table 3 presents the adjusted GMs for 9 OH-PAHs metabolized
from naphthalene (NAP), fluorene (FLU), phenanthrene (PHE) and
pyrene (PYR), using sample weighted linear regression models with
log10-sCOT and log10-UCre as covariates. Compared to nonusers, recent
Fig. 1. Category chart for identifying nonusers, recent marijuana users and cigarette smokers. Urinary PAH metabolite concentrations were available in four NHANES cycles: 2005–2006,
2007–2008, 2009–2010 and 2011–2012. Urinary VOC metabolite concentrations were available in two NHANES cycles: 2005–2006 and 2011–2012. Urinary thiocyanate concentration
was available in four NHANES cycles: 2005–2006, 2007–2008, 2009–2010 and 2011–2012. Active exclusive cigarette smokers were selected if their sCOT was N10 ng/mL, and they
self-reported cigarette smoking within the five days prior to examination, but neither used marijuana nor any other tobacco products.
Table 1
Sample size characteristics of nonusers, recent marijuana users and cigarette smokers.
Nonuser Marijuana usera Cigarette smoker
VOC PAH SCN VOC PAH SCN VOC PAH SCN
All 973 1519 3028 47 73 141 99 213 402
Gender
Male 377 636 1150 35 48 91 65 122 222
Female 596 883 1878 12 25 50 34 91 180
Race/ethnicity
Non-Hispanic White 281 424 931 30 40 82 40 88 167
Non-Hispanic Black 207 310 573 8 15 26 22 34 64
Mexican American 241 382 886 8 10 22 28 54 114
Others 244 403 638 1 8 11 9 37 57
Age (year)
18–45 702 1045 2073 33 56 104 52 118 218
≥46 271 474 955 14 17 37 47 95 184
a Participants usedmarijuanawithin 5 daysprior to theirNHANES physical examination.
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marijuana users had significantly higher concentrations for 1-OH-NAP
(p-value = 0.016), 1-OH-PYR (p = 0.002), 2-OH-FLU (p b 0.001),
3-OH-FLU (p b 0.001) and 3-OH-PHE (p = 0.011). Adjusted GMs of
2-OH-NAP, 1-OH-PHE and 2-OH-PHE were elevated more than 11%
among recent marijuana users compared to nonusers, but their
concentration levels were not statistically significantly different.
Table 4 presents the adjusted GMs for those VOC metabolites with
detection rates above 60%. Recent marijuana users had significantly
higher urinary metabolite concentrations of acrylamide (p b 0.001),
acrylonitrile (p b 0.001), 1,3-butadiene (MHBMA3, p = 0.037), and
cyanide (SCN, p b 0.001), than did nonusers. Urinary metabolites
of crotonaldehyde (4%), propylene oxide (1%), styrene (3%), and
xylene (1–15%) were elevated among recent marijuana users
compared with nonusers, but these increases were not statistically
significant (p-values from 0.07–0.73). Compared with nonusers,
the highest increase (approximately 13-fold) was observed for
N-acetyl-S-(2-cyanoethyl)-L-cysteine (CYMA, a urinary metabolite
of acrylonitrile) in recent marijuana users.
4. Discussion
We observed higher levels of many potentially toxic by-products of
combustion (PAHs and VOCs) in recent marijuana users compared to
nonusers in the present study. To our knowledge, this is the first
examination to date of body burdens of harmful organic compounds
in self-reported exclusivemarijuana users who participated inNHANES.
These findings suggest that further studies are needed to evaluate the
potential health risks to humans from the exposure to these agents
when smoking marijuana.
In order to obtain exclusive samples to evaluate the exposure to
marijuana, we excluded the participants if they had either sCOT
N10 ng/mL (Pirkle et al., 1996, 2006) or self-reported using any tobacco
products (i.e., cigarette, cigar, pipe, snuff, chewing tobacco, nicotine
patch) at the time of the survey. However, we still observed higher
GMs of tNNAL and sCOT in recent marijuana users compared with
nonusers. Since both NNAL and COT are tobacco-specific biomarkers
(Hecht et al., 2008; Wei et al., 2014), this finding suggests that recent
Table 2
Urinary metabolites of PAHs and VOCs, abbreviations and detection percentages. For the categories, refer to Fig. 1.
Parent compound Urine metabolite Detection percentage (%)
Abbreviation Nonuser Marijuana usera Cigarette smoker
Fluorene 2-Hydroxyfluorene 2-OH-FLU 100 100 100
3-Hydroxyfluorene 3-OH-FLU 100 100 100
9-Hydroxyfluorene 9-OH-FLU 100 100 100
Naphthalene 1-Hydroxynaphthalene 1-OH-NAP 99.9 100 100
2-Hydroxynaphthalene 2-OH-NAP 99.9 100 100
Phenanthrene 1-Hydroxyphenanthrene 1-OH-PHE 100 100 100
2-Hydroxyphenanthrene 2-OH-PHE 100 100 100
3-Hydroxyphenanthrene 3-OH-PHE 100 100 100
Pyrene 1-Hydroxypyrene 1-OH-PYR 100 100 100
Acrolein N-acetyl-S-(3-hydroxypropyl)-L-cysteine 3HPMA 100 100 100
N-acetyl-S-(2-carboxyethyl)-L-cysteine CEMA 97.4 97.8 100
Acrylamide N-acetyl-S-(2-carbamoylethyl)-L-cysteine AAMA 98.4 100 100
N-acetyl-S-(2-carbamoyl-2-hydroxyethyl)-L-cysteine GAMA 62.3 80.4 83.3
Acrylonitrile N-acetyl-S-(2-cyanoethyl)-L-cysteine CYMA 85.8 100 100
Benzene trans, trans-Muconic acid MU 51.2 50.0 68.8
N-acetyl-S-(phenyl)-L-cysteine PMA 29.5 28.3 42.7
1,3-Butadiene N-acetyl-S-(3,4-dihydroxybutyl)-L-cysteine DHBMA 99.6 100 100
N-acetyl-S-(4-hydroxy-2-buten-1-yl)-L-cysteine MHBMA3 95.5 95.7 100
Carbon-disulfide 2-Thioxothiazolidine-4-carboxylic acid TTCA 66.7 80.4 74.0
Crotonaldehyde N-acetyl-S-(3-hydroxypropyl-1-methyl)-L-cysteine HPMMA 99.9 100 100
Cyanide Thiocyanate SCN 100 100 100
N,N-dimethylformamide N-acetyl-S-(N-methylcarbamoyl)-L-cysteine AMCC 98.3 100 100
Ethylbenzene, styrene Phenylglyoxylic acid PGA 89.9 95.7 89.6
Propylene oxide N-acetyl-S-(2-hydroxypropyl)-L-cysteine 2HPMA 97.1 100 100
Styrene Mandelic acid MA 99.3 95.7 97.9
Toluene N-acetyl-S-(benzyl)-L-cysteine BMA 99.2 100 100
Xylene 2-Methylhippuric acid 2MHA 93.9 91.3 100
3-Methylhippuric acid + 4-Methylhippuric acid 3MHA + 4MHA 99.2 100 100
a Participants used marijuana within 5 days prior to their NHANES physical examination.
Fig. 2. Tobacco specific biomarker measurements among recent marijuana users and nonusers. (a) Least square geometric means of urinary total NNAL (pg/mL) calculated with and
without log10-transformed serum cotinine as one covariate in the multiple regression analysis. (b) Geometric means of serum cotinine among marijuana users and nonusers. Error
bars indicate 95% confidence intervals. Urinary NNAL data was available in NHANES 2007–2012.
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marijuana users were likely co-exposed to secondhand tobacco smoke
at the time when the surveys were conducted. It was also plausible
that some marijuana users might add tobacco to marijuana to assist
burning when marijuana is smoked (Hall and Degenhardt, 2009).
SCOT has been measured in every survey cycle while tNNAL was not
available before 2007 (Bernert et al., 2010; Wei et al., under review,
2015b, 2015c), we thus included log10-sCOT as a covariate in the
regression analysis to account for the confounding from tobacco
smoke. Equal adjusted GMs of tNNAL between recent marijuana users
and nonusers (Fig. 2) indicates the effectiveness of this approach.
Previous studies have documented PAHs from tobacco combustion,
but few studies have characterized PAH levels in marijuana smoke.
Under controlled laboratory conditions, Moir et al. (2008) measured
PAH concentrations in both mainstream and sidestream marijuana
smoke, and they found the pattern of chemicals in tobacco smoke was
similar to that in marijuana smoke. Using the biomonitoring data, we
found that recent marijuana users had significantly higher adjusted
GMs of 1-OH-NAP, 2- and 3-OH-FLU, 3-OH-PHE and 1-OH-PYR than
did nonusers (Fig. 3 and Table 3). These results confirm that marijuana
smoke is an important source of exposure to PAHs.
OH-PAH levels in marijuana users were generally lower compared
with cigarette smokers, which was consist with the earlier report of
lower PAH concentrations in mainstream marijuana smoke compared
with mainstream tobacco smoke (Moir et al., 2008), except for 1-OH-
Pyre.We observed elevated adjusted GM level of 1-OH-PYR in exclusive
marijuana users than in cigarette users although the difference was
not statistically significant. This difference could be attributed to the
variations resulted from different sampling duration since last sub-
stance (cigarette or marijuana) use. Small sample size for marijuana
users could also introduce large variation. Future studies are needed to
better characterize biomarker patterns among substance user groups,
while accounting for such factors as use frequency and amount of prod-
uct consumed.
Significantly higher adjusted GMs formany urinary VOCmetabolites
in recent marijuana users than in nonusers suggest that marijuana
smoke is also an important source of exposure to a number of toxic
Table 3
Adjusted geometricmeans (95% confidence interval) of urinary concentrations (pg/mL) of PAHmetabolites in nonusers, marijuana users, and cigarette smokers. For the categories, refer to
Fig. 1. Estimates were computed using sample weighted linear regression models with log10-sCOT and log10-UCre as covariates.
PAH metabolite Adjusted geometric means (95% CI), pg/mLa p-Valued R2
Nonuser Marijuana userb Cigarette smokerc
1-OH-NAP 1498 (1351, 1661) 2995 (1787, 5019) 5926 (3550, 9892) 0.016 0.29
2-OH-NAP 3214 (3015, 3428) 3661 (3037, 4413) 9471 (6730, 13,328) 0.233 0.44
2-OH-FLU 199 (189, 209) 322 (252, 411) 581 (463, 729) b0.001 0.64
3-OH-FLU 71.4 (67.7, 75.4) 138 (111, 172) 255 (198, 330) b0.001 0.65
9-OH-FLU 254 (239, 270) 246 (203, 298) 300 (216, 417) 0.732 0.45
1-OH-PHE 125 (119, 132) 162 (128, 205) 162 (123, 212) 0.057 0.44
2-OH-PHE 61 (58.3, 63.9) 68 (55.2, 83.8) 71 (55.5, 90.9) 0.349 0.46
3-OH-PHE 68.3 (65, 71.9) 91.8 (74.8, 113) 97.1 (75.6, 125) 0.011 0.50
1-OH-PYR 95.8 (90.9, 101) 157 (119, 206) 127 (95, 168) 0.002 0.45
Abbreviations: CI— confidence interval; R2 — coefficient of determination.
a Sample sizes for nonusers, recent marijuana users, cigarette users were 1519, 73, and 213, respectively.
b Participants used marijuana within 5 days prior to their NHANES physical examination.
c Exclusive cigarette smokerswere selected if their sCOTwas N10 ng/mL, and they self-reported cigarette smokingwithin thefive days prior to examination, but neither usedmarijuana
nor any other tobacco products.
d p-Values between recent marijuana user and nonusers using Satterwaite-adjusted F test.
Table 4
Adjusted geometric means of VOC metabolites among nonusers, marijuana users, and cigarette users. For the categories, refer to Fig. 1. Estimates were computed using sample weighted
linear regression models with log10-sCOT and log10-UCre as covariates.
VOC metabolite Adjust geometric means (95% CI), ng/mLa p-Valuee R2
Non-user Marijuana userb Cigarette smokerd
CEMA 77.5 (73.4, 81.8) 82.7 (65.5, 105) 118 (78.7, 176) 0.629 0.52
3HPMA 241 (228, 255) 274 (229, 328) 642 (429, 960) 0.213 0.50
AAMA 40.2 (37.6, 42.9) 97.1 (72.7, 130) 67.2 (46.8, 96.7) b0.001 0.52
GAMA 15.1 (14.1, 16.2) 29.2 (20.7, 41.1) 25.1 (18.4, 34.3) 0.002 0.43
CYMA 1.44 (1.34, 1.56) 15.4 (8.15, 29) 24 (15.0, 38.5) b0.001 0.77
DHBMA 221 (207, 235) 252 (221, 287) 257 (195, 339) 0.070 0.66
MHBMA3 4.85 (4.44, 5.30) 7.06 (5.08, 9.81) 32.4 (18.8, 56) 0.037 0.52
HPMMA 303 (287, 320) 316 (261, 383) 1180 (789, 1766) 0.689 0.56
SCNc 850 (799, 904) 1682 (1437, 1969) 2957 (2364, 3698) b0.001 0.44
AMCC 84.4 (76.2, 93.4) 107 (81.4, 141) 340 (215, 539) 0.138 0.46
PGA 116 (106, 128) 139 (105, 183) 152 (90, 256) 0.180 0.37
2HPMA 46.4 (42.6, 50.6) 49 (39.8, 60.3) 116 (74.5, 180) 0.633 0.28
MA 135 (127, 144) 143 (116, 176) 221 (143, 343) 0.645 0.55
BMA 6.60 (6.10, 7.14) 6.15 (4.53, 8.36) 6.49 (4.07, 10.4) 0.678 0.35
2MHA 27.3 (24.6, 30.4) 30.3 (21.5, 42.8) 85.8 (50.7, 145) 0.612 0.29
3MHA + 4MHA 174 (157, 194) 221 (172, 284) 631 (406, 980) 0.152 0.41
TTCA 8.64 (7.54, 9.89) 9.32 (6.21, 14.0) 4.93 (2.47, 9.87) 0.730 0.13
Abbreviations: CI— confidence interval; R2 — coefficient of determination.
a Sample sizes for nonusers, recent marijuana users, and cigarette users except thiocyanate were 973, 47, and 99, respectively.
b Participants used marijuana within 5 days prior to their NHANES physical examination.
c Sample sizes of thiocyanate for nonuser, marijuana user, and cigarette user were 3028, 141, and 402, respectively.
d Exclusive cigarette smokerswere selected if their sCOTwas N10ng/mL, and they self-reported cigarette smokingwithin thefive days prior to examination, but neither usedmarijuana
nor any other tobacco products.
e p-Values between recent marijuana user and nonusers using Satterwaite-adjusted F test.
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VOCs. Recent marijuana users had slightly elevated adjusted GMs of
urinary TTCA (metabolite of CS2). A previous study reported that each
commercial cigarette and marijuana cigarette could deliver approxi-
mately 2 μg CS2 in mainstream smoke (Horton and Guerin, 1974), but
caution should be used when reviewing these data as Pankow et al.
(2004) reported higher CS2 concentration in mainstream tobacco
smoke. Furthermore, no recent data is available for the concentrations
of CS2 in marijuana smoke. Other factors that could plausibly explain
these concentration differences include planting environment/soil
characteristics, fertilizers used, product storage, smoking conditions
and other exposure sources such as diet.
Adjusted GMs of urinary CYMA (metabolite of acrylonitrile),
MHBMA3 (metabolite of 1,3 butadiene) in recent marijuana users
were nearly 13 times and 1.5 times of those in nonusers, respectively,
but significantly lower than in cigarette users. In contrast, Moir et al.
(2008) found higher concentrations of acrylonitrile and 1,3-butadiene
in both mainstream and sidestream marijuana smoke compared
with those in tobacco smoke. The best plausible explanation for
this observation, similar to that of the OH-PAHs, could be the lower
frequency of marijuana smoking and the smaller amount of product
consumed by marijuana users (Jamal et al., 2014; SAMHSA, 2014).
Most PAHs and VOCs are ubiquitous in the environment and none of
them are marijuana-specific compounds. Other sources, such as vehicle
exhaust, coal combustion and diet, could be important exposure sources
(Li et al., 2008; Alwis et al., 2012). These sources could ‘dilute’ the con-
tributions to the body burdens from marijuana smoke especially when
marijuana was infrequently used and the amount consumed was
small. In addition, some VOC metabolites, i.e. BMA, can be formed
from multiple sources (Lovreglio et al., 2010). For example, benzyl
alcohol, a widespread constituent in cosmetic products can be me-
tabolized into BMA. Other factors that cannot be ruled out include
differences in the absorption, distribution, metabolism and excretion
mechanisms of the chemicals in human body. Collectively, these
factors might explain the inconsistent statistical results for the
multiple metabolites of fluorene and phenanthrene.
Our findings should be interpreted in the context of several limita-
tions. The sparsity ofmarijuana users precluded demographical analysis
and comprehensive exposure characterization but itwas still possible to
evaluate differences in biomarker levels between marijuana users and
nonuser categories. Although screened from a representative sample
of the general US population, owing to small sample sizes, the results
presented in this study could not reflect overall marijuana exposure
characteristics in the US population, but rather be informative to
plan future systematic assessment of exposure to marijuana use.
Due to the ubiquity of PAHs and VOCs in environment, this study as-
sumed that contributions frombackground sources (i.e. vehicle exhaust,
gas/oil/coal, wood smoke, dietary, etc.) occurred at comparable levels
across different categories. Comparison of biomarker levels between
cigarette smokers and marijuana users was also limited and requires
further exploration by including detailed product use information
(i.e. use frequency and amount) in the regression analysis. Characterizing
exposure patterns among persons using multiple combustion products
are also needed. Higher concentrations for many PAHs and VOCs in
sidestream marijuana smoke compared to sidestream tobacco smoke
(Moir et al., 2008) suggest higher potential risks of persons being exposed
to harmful constituents in secondhand marijuana smoke (SHMS)
than secondhand tobacco smoke under comparable smoking and
environmental conditions. Unfortunately, neither laboratory mea-
surements nor the questionnaire data from NHANES surveys are
available to identify the respondents exposed to SHMS. Furthermore,
a highly accurate and sensitive laboratory method (Wei et al.,
2015c), measuring marijuana-specific psychoactive constituents,
such as Δ9-THC, and their metabolites in biological matrices, would
be helpful to assess actual exposure to both firsthand and secondhand
marijuana smoke in future studies.
5. Conclusions
This study reported for the first time identified higher levels ofmany
potentially toxic by-products of combustion (PAHs and VOCs) among
recent marijuana users than nonusers. These findings suggest that
further studies are needed to evaluate potential health risks to humans
from the exposure to these agents when smoking marijuana.
Meanwhile, future work, such as assessing exposure characteristics
and health risks in large-scale marijuana users using a sensitive
biomonitoring method for measuring marijuana-specific
Fig. 3. Adjusted geometric means (GMs) of urinary concentrations of thiocyanate, metabolites of acrylamide, acrylonitrile and pyrene among nonusers, recent marijuana users (MJ user),
and cigarette smokers (Cig. Smoker). Categories refer to Fig. 1. Estimates were computed using sample weighted linear regression models with log10-sCOT and log10-Cre as covariates.
Error bars indicate 95% confidence intervals.
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cannabinoids and their metabolites are recommended for a better
evaluation of marijuana smoke exposure.
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